Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Iron
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 11, 2025
Lead Product(s) : Iron
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Royal Adelaide Hospital | Austin Health | Flinders Medical Centre | Peter MacCallum Cancer Centre | South Australian Health and Medical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Iron
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Royal Adelaide Hospital | Austin Health | Flinders Medical Centre | Peter MacCallum Cancer Centre | South Australian Health and Medical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Thomas Jefferson University | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of Colorado, Denver | Institute of Nutrition of Ce
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention of Iron Deficiency Anemia Post-delivery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : Iron
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Thomas Jefferson University | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of Colorado, Denver | Institute of Nutrition of Ce
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Infant Formula Update: June 17, 2022
Details : Aptamil (Iron) First Infant Milk Stage 1(This infant formula is appropriate for most infants and meets U.S. nutrient requirements, but it may not be suitable for infants born prematurely, or with a low birth weight.
Product Name : Aptamil
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 17, 2022
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Clinres Farmacija
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of >Your< Iron Syrup Supplementation in Children With Dietary Iron Deficiency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 19, 2021
Lead Product(s) : Iron
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Clinres Farmacija
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Folic Acid,Iron
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Cipla
Deal Size : $12.3 million
Deal Type : Acquisition
Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.
Details : Cipla has acquired the four brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in the women's health segment, Cipla said in a filing to the BSE.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
July 02, 2020
Lead Product(s) : Folic Acid,Iron
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Cipla
Deal Size : $12.3 million
Deal Type : Acquisition
Lead Product(s) : Iron
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Danone Nutricia Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Iron Absorption From a Wheat-based Instant Cereal:Gut and Stable Isotope Studies in Kenyan Infants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 28, 2019
Lead Product(s) : Iron
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Danone Nutricia Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Worldwide Clinical Trials | Fresenius Medical Care
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 11, 2017
Lead Product(s) : Iron
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Worldwide Clinical Trials | Fresenius Medical Care
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 11, 2014
Lead Product(s) : Iron
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Luoxis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : Iron
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Luoxis
Deal Size : Inapplicable
Deal Type : Inapplicable